Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine

Journal of Gastrointestinal Oncology

Volumn 3, Issue 3, 2012, Pages 243-250

  Van Ness, Michael ^a   Gregg, Jeffrey ^a   Wang, Jun ^b   Chen, Mingyi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastric malignancy; Genetics and molecular pathology; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; IMATINIB; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CAUSE OF DEATH; CELL CYCLE; CELL GROWTH; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL TECHNIQUE; TUMOR RESISTANCE;

EID: 84995740348     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2012.017     Document Type: Review

References (33)

1. Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50.
2. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-72.
3. Khan FA, Shukla AN. Pathogenesis and treatment of gastric carcinoma: " an up-date with brief review" . J Cancer Res Ther 2006;2:196-9.
4. Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter Pylori associated global gastric cancer burden. Front Biosci 2009;14:1490-504.
5. Valle J, Gisbert JP. Helicobacter pylori infection and precancerous lesions of the stomach. Hepatogastroenterology 2001;48:1548-51.
6. Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011;17:2693-701.
7. Giaginis CT, Vgenopoulou S, Tsourouflis GS, et al. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res 2009;15:173-81.
8. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010;376:687-97.
9. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
10. Cervera P, Fléjou JF. Changing pathology with changing drugs: tumors of the gastrointestinal tract. Pathobiology 2011;78:76-89.
11. Laurini JA, Carter JE. Gastrointestinal stromal tumors: a review of the literature. Arch Pathol Lab Med 2010;134:134-41.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
13. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33:1401-8.
14. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
15. Lennartsson J, Blume-Jensen P, Hermanson M, et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 1999;18:5546-53.
16. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.Am J Surg Pathol 2006;30:90-6.
17. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
18. Chen H, Hirota S, Isozaki K, et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 2002;51:793-6.
19. Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2010;21:208-15.
20. Christopoulos C, Balatsos V, Rotas E, et al. The syndrome of gastric carcinoid and hyperparathyroidism: a family study and literature review. Eur J Endocrinol 2009;160:689-94.
21. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-72.
22. Wunderlich A, Arndt T, Fischer M, et al. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J Surg Oncol 2012;105:357-64.
23. Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol 2011;24:S53-7.
24. Fontaine J, Le Douarin NM. Analysis of endoderm formation in the avian blastoderm by the use of quail-chick chimaeras. The problem of the neurectodermal origin of the cells of the APUD series. J Embryol Exp Morphol 1977;41:209-22.
25. Modlin IM, Kidd M, Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg 2002;168:669-83.
26. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009;16:72-8.
27. Leotlela PD, Jauch A, Holtgreve-Grez H, et al. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-50.
28. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
29. Bosman FT, World Health Organization. International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010:417p.
30. Furlan D, Cerutti R, Uccella S, et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 2004;10:947-57.
31. Bakkelund K, Fossmark R, Nordrum I, et al. Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem 2006;54:615-21.
32. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010;29:19.
33. Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011;14:161-5.